Gilead Sciences, Inc. announced that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this transition over the next several months. Dr. Parsey joined Gilead in November 2019 and is responsible for overseeing the company?s global clinical development and medical affairs organizations.

During his tenure, he led the growth of the development organization, specifically with the advancement of market leading treatments in virology and the establishment of Gilead?s oncology pipeline and therapeutics.